Shares in ValiRx PLC (LON:VAL) rose 2% after the life sciences specialist said it would be presenting research data at a leading oncology get-together in the US next month.
The American Association for Cancer Research Annual Conference will take place in New Orleans, starting April 16.
As well as presenting, the AIM-listed firm will use the event, which attracted 20,000 healthcare professionals last year, to promote its “products, therapeutics and services” to specialists.
In particular it will use the opportunity to further publicise the “excellent results” being seen in the clinical trial of VAL201 for difficult to prostate cancer.
"This is another great opportunity for us to show the excellence of our technology and products in a large international arena," said ValiRx chief executive Satu Vainikka.
At 8.20am, the shares were up 0.15p at 8.4p – a rise of almost 2%.